In the News...
BioPartnering North America 2010
See Topica’s corporate presentation from the BioPartnering North America 2010 Conference in Vancouver, BC Jan 25, 2010.
Click here to view the PDF.
The 8th Annual BIO Investor Forum
Thursday October 29 at 9:30 a.m. Pacific Time at the Palace Hotel in San Francisco.
Click here to view the press release.
The 2009 Life Sciences and Healthcare Venture Summit
Tuesday October 27, at 11:40 a.m. Eastern Time at the Digital Sandbox Network Event Center at 55 Broad Street in New York.
Click here to view the press release.
M2 Pharma, October 6, 2009
Topica reports encouraging Phase II results for topical antifungal luliconazole in athlete's foot.
Click here to view the full text of the article.
The Pink Sheet, July 21, 2009
Ex-Genentech CEO & Industry Expert Joins Topica As Chairman Of The Board
Citing Topica’s appointment of its new board chairman, G. Kirk Raab, former president and chief executive officer of Genentech, as a “coup for Topica”, this article shows why Topica president Greg Vontz and Mr. Raab are so keen on bringing luliconazole to the marketplace.
Click here to view the full text of the article.
Start-Up Magazine, May 2009
...the compound is already approved in Japan for tinea infections. Topica’s initial focus will be on advancing ongoing clinical trials of the drug in athlete’s foot ... a market IMS estimates to be approximately $400 million in the US alone...
Click here to view the full text of the article.
Reuters, April 22, 2009
This article cites the clinical experience in Japan, where luliconazole has been prescribed for tinea infections since 2005. With a patient base of approximately 4 million, the drug has established an excellent record for efficacy, safety, and a shortened course of treatment.
Click here to view the full text of the article.
Medical News Today, April 23, 2009
This story notes that luliconazole is "one of the most potent and broad spectrum molecules in the imidazole class of antifungal agents" which "...has the ability to easily penetrate the toenail achieving rapid fungal eradication in the nail bed..."
Click here to view the full text of the article.
bioportfolio.com, April 22, 2009
This story describes Topica’s multi-center, randomized double-blind Phase II study of luliconazole in tinea pedis, noting that “The primary efficacy endpoint is to achieve complete clearance of the infection at two weeks post treatment.”
Click here to view the full text of the article. |
